BioSpace News Archive

Phase 1b/2 Trial of Vecabrutinib in 400 mg Cohort; Clinical Update at Upcoming ASH Annual Meeting

Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced financial results for the third quarter ended September 30, 2019, and provided an overview of recent developments.

BioDelivery Sciences International, Inc., a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, reported strong financial results for the third quarter ended September 30, 2019, as well as the following operational and performance highlights.

On track to have four Phase 2 studies ongoing by year end across pipeline of CNS product candidates

Organogenesis Holdings Inc. reported financial results for its third quarter ended September 30, 2019.

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced its intention to offer and sell 2,000,000 shares of its Class A common stock in an underwritten public offering pursuant to an existing shelf registration statement.

Disclosed complement C3 as the target for NGM621, an inhibitory antibody intended to treat patients with dry age-related macular degeneration (AMD)

Total Revenues Increase 81% to $46.2 million Compared to $25.6 million in Prior-year Period

Approximately 90% of Patients Treated with INGREZZA in the Open-Label KINECT 4 Phase III Study Achieved a 50% or Greater Improvement in Their Tardive Dyskinesia Symptoms

Updates 2019 financial guidance to reflect CBS acquisition, introduces preliminary 2020 revenue guidance of $50 to $56 million